^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor) +
    bendamustine (DNA replication inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer

    Excerpt:
    ...- Advanced or metastatic Her2-negative breast cancer, histologically confirmed...
    Trial ID:
    NCT01891227
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ther Adv Med Oncol
    Title:

    Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)

    Published date:
    10/19/2021
    Excerpt:
    AGMT MBC-6 is a multicentre, open-label, single-arm phase II study in HER2-negative MBC....With 17 partial and one complete remission, ORR was 46%. Median progression-free survival (PFS) was 7.5 months...The combination of capecitabine and bendamustine shows promising efficacy and moderate toxicity.
    DOI:
    10.1177/17588359211042301
    Trial ID:
    NCT01891227